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Microglia are the tissue macrophages of the CNS. Microglial activation coupled with 
macrophage infiltration is a common feature of many classic neurodegenerative 
disorders. The absence of cell-type specific markers has confounded and complicated 
the analysis of cell-type specific contributions toward the onset, progression, and 
remission of neurodegeneration. Molecular screens comparing gene expression in 
cultured microglia and macrophages identified Golli-myelin basic protein (MBP) as a 
candidate molecule enriched in peripheral macrophages. In situ hybridization analysis of 
LPS/IFNg and experimental autoimmune encephalomyelitis (EAE)–induced CNS 
inflammation revealed that only a subset of CNS macrophages express Golli-MBP. 
Interestingly, the location and morphology of Golli-MBP+ CNS macrophages differs 
between these two models of CNS inflammation. These data demonstrate the difficulties 
of extending in vitro observations to in vivo biology and concretely illustrate the complex 
heterogeneity of macrophage activation states present in region- and stage-specific 
phases of CNS inflammation. Taken altogether, these are consistent with the emerging 
picture that the phenotype of CNS macrophages is actively defined by their molecular 
interactions with the CNS microenvironment.  
KEYWORDS: microglia, macrophages, neuroinflammation, autoimmunity  
 
INTRODUCTION 
The mammalian CNS is populated very early in prenatal development by tissue macrophages[1,2,3,4]. By 
adulthood, this CNS-resident population of macrophages, referred to as microglia, are found in all regions 
of the brain and spinal cord, and comprise ~10–15% of the total cells found in the CNS[1,2,3,4]. Despite 
a century of study, the in vivo function of microglia is still a subject of debate. In vitro studies have 
conclusively demonstrated the neurodestructive potential of microglia when activated by pathogenic 
stimuli[1,2,3,4]. Conversely, the conservation of the relative concentration and distribution of microglia 
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throughout the CNS across all mammalian species so far examined suggests an important evolutionarily 
conserved function for these cells in maintaining CNS function. As yet, a viable (spontaneous or 
transgenically engineered) mammalian model that lacks all microglia does not exist. The absence of such 
a microglial knockout model has prevented conclusive and direct identification of the necessary and 
nonredundant neurosupportive functions provided by CNS-resident microglia.  
An additional complication confounding this debate is that the CNS is served by at least two types of 
macrophage populations. One population is defined by a CD45lo phenotype, is located predominantly in 
the CNS parenchyma, and appears to be rarely replenished from hematogenously derived cells in the 
mature adult[1,2,3,4]. The second population of cells is defined by a CD45hi phenotype; is located 
predominantly in perivascular regions, meninges, and choroids plexus; and is frequently replaced by 
hematogenously derived cells every few weeks[1,2,3,4]. The latter population is alternatively referred to 
as perivascular microglia or perivascular macrophages, while the former is most commonly referred to as 
parenchymal microglia. The absence of cell-type specific markers able to distinguish these two 
populations in histological analysis of CNS pathologies has hindered the definition of their relative roles. 
Consequently, many investigators choose to refer to all macrophages located within the CNS as 
microglia, even including those infiltrating from the bloodstream[5]. 
Three types of studies suggest that both types of microglia (long-term residents and acutely 
infiltrating cells) can play neuroprotective functions and that the source of microglia may determine their 
functions. For example, op/op mice are deficient in macrophage-colony stimulating factor (M-CSF) and 
consequently have ~30–40% fewer macrophages in all organs, including the CNS[6,7]. While the CNS of 
op/op mice appears histologically indistinguishable from wild-type mice, op/op mice display severe 
neurological deficits, including impaired auditory and visual processing, with specific abnormalities 
associated with cerebral cortex function[7]. In addition, M-CSF enhances neuronal process extension in 
vitro, but only in cultures with M-CSF receptor–expressing microglia[6]. Interestingly, while wild-type 
mice do not develop spontaneous, nontransgenically induced features of Alzheimer’s disease, op/op mice 
have been reported to develop A-beta plaques spontaneously[8]. Injection of M-CSF not only increases 
the numbers of CNS microglia by nearly 70%, but it also decreases the number of amyloid plaques found 
in the op/op CNS. While these data suggest that CNS macrophages are essential for optimal neuronal 
development and function, they do not conclusively reveal the relative importance or roles of the two 
types of CNS macrophages. 
The human syndrome called Nasu-Hakola’s disease provides another compelling example that CNS 
macrophages contribute to optimal neurological function[9,10]. Individuals with Nasu-Hakola’s disease 
lack a functional TREM2 pathway and develop early-onset cognitive dementia in their 20s and 30s. 
Surprisingly, within the CNS, only microglia express detectable TREM2 mRNA[11,12]. In addition, 
CNS-resident (CD45lo) microglia express ~10-fold higher levels of TREM2 than acutely infiltrating 
(CD45hi) macrophages[11,13]. These data suggest that aberrant microglial function can trigger clinical 
symptoms normally associated with a primary dysfunction in CNS neurons!  
Finally, in vivo studies using irradiation bone marrow chimeras suggest that both acutely infiltrating 
macrophages and long-term CNS-resident cells each can play distinct and nonredundant neuroprotective 
functions. In irradiation bone marrow chimeric mice, the host bone marrow is killed by irradiation and 
replaced by genetically distinct donor bone marrow[4]. Using this method, Rivest and colleagues 
demonstrated that hematogenously derived macrophages were more phagocytic than CNS-resident 
microglia[5]. Additionally, they found that the failure to retain or to recruit continually these donor-
derived macrophages to the CNS correlated with increased amyloid plaque deposition in murine models 
of Alzheimer’s disease[5]. Using similar methods, Byram et al. demonstrated that peripheral myeloid 
cells were essential to initiate protective T-cell responses inhibiting motoneuron death following facial 
axotomy[14]. However, Byram et al. also demonstrated that CNS-resident cells were absolutely essential 
to evoke or sustain the neuroprotective response; acutely infiltrating macrophages alone were insufficient. 
Taken together, these data illustrate that all populations of CNS macrophages are likely to play specific 
and essential functions to maintain optimal neuronal function. The implication of these data is that 
dysfunction in any CNS macrophage compartment also has the potential to facilitate or directly contribute to 
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the onset and progression of clinical CNS neurodegeneration. Effective and targeted therapeutic intervention 
for CNS neurodegenerative diseases is thus likely to depend on identifying the relative contributions of each 
CNS macrophage population as a function of defined stages of each type of CNS neurodegeneration. As a 
first step toward this goal, we and others have conducted gene-profiling screens to define molecules that are 
enriched in each cell type[11,13,15,16]. Here we characterize the induced expression of a specific Golli-
myelin basic protein (Golli-MBP), referred to as BG21, which was identified by our screens as being 
regulated by inflammatory signals and enriched in peripheral macrophage populations[17].  
The classic MBPs are produced primarily by CNS oligodendrocytes[17,18]. Within the CNS, the 
classic forms of MBPs function to maintain CNS myelin structure. Low, but detectable, expression of 
classic MPBs can also be detected in several sites outside the CNS, including peripheral myelin and the 
thymus[17,18]. Golli-MBPs are not structural myelin proteins[17], however, they do share exons and 
antigenic protein domains with classic MBPs due to alternative splicing of MBP exons into a transcript 
initiated by the Golli-promoter upstream from the classic MBP promoter (Fig. 1a)[17]. Golli-MBPs are 
expressed by neurons, oligodendrocytes, as well as a wide variety of immune cells, including most 
peripheral macrophage populations[19,20]. High doses of LPS also have been reported to induce Golli-
MBP expression in rodent neonatal and human fetal cultured microglia[21]. In addition, Golli-MBP 
immunoreactivity has been reported in microglia and/or CNS-infiltrating macrophages surrounding 
inflammatory lesion in CNS tissue taken from human multiple sclerosis (MS) patients[21]. 
MS is an autoimmune disorder characterized by targeted inflammation of CNS white matter coupled 
with oligodendrocyte death and demyelination[22]. Myeloid expression of Golli-MBPs has alternatively 
been hypothesized to promote destructive inflammatory demyelinating episodes of MS and to promote 
remission and repair phases of MS[19]. By presenting their own self-expressed MBP peptides to 
autoreactive MBP-specific T cells, Golli-MBP+ myeloid cells could serve to drive activation of 
destructive myelin-specific T cells. Conversely, production and secretion of Golli-MBP proteins from 
cultured microglia does promote the proliferation of oligodendrocyte precursors in vitro and in 
organotypic slice cultures[21]. Thus Golli-MBP production may also serve to remediate the consequences 
of autoimmune T-cell activation by promoting CNS repair.  
As yet, a comparison of Golli-MBP mRNA expression in the healthy vs. inflamed CNS has not been 
reported. Here we explore the general utility of using Golli-MBP to label CNS macrophage populations in 
two acute/remitting murine models of CNS inflammation: LPS/IFNg-induced inflammation and 
experimental autoimmune encephalomyelitis (EAE).  
MATERIALS AND METHODS 
Cells and Tissues 
Microglia were isolated by flow cytometry from C57BL/6J neonatal mixed glial culture as previously 
described using phycoerythrin (PE)-conjugated antibodies directed against Fc receptor (FcR)/CD16/CD32 
(Pharmingen, San Diego, CA)[11]. Peritoneal macrophages were isolated from C57Bl/6J mice following 
thioglycolate injections as previously described[11]. Cells were treated for 1 or 22 h with LPS (100 
ng/ml) and IFNg (10 U/ml). 
Northern Blot Analysis 
poly(A) RNA, 2 µg per lane, was resolved by electrophoresis in a 1.5% agarose/1.2 M formaldehyde gel, 
transferred to nylon membrane, and hybridized with 32P-radiolabeled probe corresponding to Golli-MBP 
exon 5a (accession #L07508 nucleotides 414-627) as described previously[11]. Expression of each 
transcript was quantified using NIH MAGE 1.62 software (National Institutes of Mental Health, Bethesda, 
MD). The actin loading control for the northern blot depicted in Fig. 1B has been previously published[11].  
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FIGURE 1. Golli-MBP expression is enriched in culture macrophages as compared to cultured 
microglia. (A) The exon structures of two Golli-MBP transcripts are schematically represented. 
Exons encoding Golli-specific amino acids are depicted in white, exons encoding “classic” MBP 
amino acids are depicted in grey. The single asterisk/grey line identifies the sequence from exon 
5c used for in situ hybridization probes (Figs. 2 and 3). The double asterisk/grey line identifies the 
sequence from exon 5a used for northern blot probes (Fig. 1B, C). (B and C) Northern blot 
analysis of mRNA isolated from microglia, purified by flow cytometry from mixed glial cultures 
and thioglycolate-elicited peritoneal macrophages. Cells were either untreated or treated for 22 h 
with LPS/IFNg. The dark single arrow indicates the 5.1-Kb BG21 transcript, the double arrow 
indicates the 2.6-Kb J37 transcript. “B” represents a 16-h exposure and “C” represents a 2-week 
exposure of the same northern blot.  
Mice 
LPS (100 ng/ml) and IFNg (10 U/ml) were injected intracerebrally into the striatum of C57Bl/6J mice in a 
total volume of 5 µl after mice had been anesthetized with metofane. Mice were euthanized at 0, 6hrs, 1 
day and 3 days after LPS/IFNg injection, and their CNS was fixed with 4% paraformaldehye by 
intracardiac perfusion followed by 24-h postfixation.  
A MBP-induced form of remitting EAE was induced as previously described[23]. Briefly, B10.PL 
mice, 6–8 weeks old, obtained from The Jackson Laboratory (Bar Harbor, ME) were injected s.c. over 
four sites on the flank with 200 µg of MBP in CFA containing 200 µg killed Mycobacterium tuberculosis, 
Jamaica strain. Pertussis toxin (List Biological Laboratories, Campbell, CA), 150 ng in 0.2 ml of PBS, 
was given i.p. at the time of immunization and 48 h later. Mice with full paralysis of both hind limbs were 
assigned an acute EAE score of 4 and euthanized. Acute EAE occurred within 14 days of immunization 
and remission of clinical symptoms occurred within 28 days of immunization. CNS tissue was harvested 
as described above from three to six mice for each condition and time point. 
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In situ Hybridization Analysis 
In situ hybridization was performed on free-floating brain cryosections and on slides mounted for lymph 
node sections as described previously[11]. Briefly, 25-µm sections were hybridized overnight at 55°C 
with 33P-labelled riboprobes (107 cpm/ml) corresponding to the final 400 nucleotides of the untranslated 
region in Golli-MBP exon 5c. Myeloid cells and blood vessels were visualized with biotinylated tomato 
lectin (Sigma) and streptavidin-horseradish peroxidase. After dipping in Ilford K-5 emulsion 
(Polysciences, Warrington, PA), slides were exposed for 4 weeks and developed with Kodak D19 
developer (Fisher Scientific). Nuclei were counterstained with Mayer’s hematoxylin.  
RESULTS AND DISCUSSION 
Golli-MBP Expression is Expressed at Much Higher Levels in Macrophage than 
Microglia In Vitro 
In the mouse, two Golli-MBP transcripts have been reported that contain both Golli-specific and MBP 
domains: BG21 and J37 (Fig. 1A)[18]. The BG21 transcript encodes Golli amino acids 1-133 spliced to 
MBP amino acids 1-56 spliced to five additional Golli-specific amino acids. J37 transcript encodes Golli 
amino acids 1-133 spliced to MBP amino acids 1-102 spliced to MBP amino acids 155-168. On the RNA 
level, exon 5A is present in both transcripts, while exon 5c is present in only BG21. As part of our 
ongoing studies to define cell-type specific molecular fingerprints, we compared the expression of BG21 
and J37 in primary microglia and thioglycolate-elicted peritoneal macrophages.  
In Fig. 1, the same northern blot has been exposed for a short (Fig. 1B,16 h) and long (Fig. 1C, 2 
week) time periods so that the expression of both the 5.1-Kb BG21 and the 2.6-Kb J37 transcripts could 
be compared between all of the microglia and macrophage samples. In general, Golli-MBP expression 
was ~10-fold higher in all macrophages (treated and untreated) than in microglia. In addition, the ratio of 
BG21:J37 transcripts differed between untreated and LPS/IFNg-treated cells. In untreated microglia and 
macrophages, the ratio of these two transcripts was ~equivalent; while BG21 levels were 1.5-fold higher 
than J37 levels in LPS/IFNg-treated microglia and more than 5-fold higher in LPS/IFNg-treated 
macrophages. In contrast to previous reports, we did not see a sustained increase in Golli-MBP 
expression, although a transient >5-fold increase in BG21 expression was detected within 1 h of 
LPS/IFNg treatment.  
The difference between our study and previous reports may be due the differences in the doses of LPS 
used and our detection methods[21]. In our studies, we used 100 ng/ml, which was a 25- to 50-fold lower 
dose than was required to observe an effect in previous reports. In addition, we examined mRNA 
production rather than Golli-MBP immunoreactivity. 
Detectable Expression of Golli-MBP is Rare in the CNS of Untreated and LPS-
IFNg-Injected Mice 
Because BG21 was expressed at a much higher level than J37 in activated macrophages, we chose to 
focus primarily on characterizing the expression of BG21 by in situ hybridization analysis in two different 
models of CNS inflammation: intracerebral injection of LPS/IFNg and EAE. For these studies, microglia, 
macrophages, and blood vessels were identified by their ability to bind tomato lectin.  
We have previously demonstrated that intracerebral injections of LPS/IFNg cause a robust, but 
transient, infiltration of activated CD45hi macrophages into the CNS and a transient activation of resident 
CD45lo microglia[11]. Unactivated macrophages in vitro expressed high levels of Golli-MBP (Fig. 1B, 
C), therefore, we examined the brain regions known to be populated by CD45hi, hematogenously derived 
cells; specifically the perivascular regions, the chorioid plexus, and the meninges. We could detect Golli-
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MBP expression in many lectin-negative cells, consistent with many previous characterizations of Golli-
MBP expression in the CNS[17]. However, we could not detect Golli-MBP mRNA expression in any 
lectin-positive cells in any brain regions by in situ hybridization analysis in the CNS of untreated control 
mice (data not shown). This is unlikely to be a strain-specific effect as identical results were observed in 
untreated control tissue C57Bl/6J, BALB/c, B10.D2, and B10.PL mice. 
In contrast, Golli-MBP mRNA was clearly detected in small numbers of lectin+ cells by 1 day post-
LPS/IFNg injection. These Golli-MBP macrophages were almost always found in close proximity to the 
injection site, but did not necessarily display the most activated macrophage morphology visible within 
the same regions (Fig. 2). The limited Golli-MBP expression observed at 1 day post-LPS/IFNg injection 
is unlikely to reflect limited macrophage infiltration or limited microglial activation. In this same model, 
we have previously reported that macrophages throughout the entire CNS of injected are rapidly induced 
to express high levels of interferon response gene 2 (IRG2) by 1 day postinjection[11]. By 3 days 
postinjection, Golli-MBP expression could no longer be detected in any population of CNS macrophages. 
This observed loss of Golli-MBP expression in lectin+ cells also correlated with the outflux of acutely 
infiltrating CD45hi macrophages from the CNS. It is also important to note that we did not observe any 
change in the level or percentage of Golli-MBP expression in lectin-negative cells as a function of this 
treatment. 
 
 
 
FIGURE 2. Golli-MBP expression is detected in only a few CNS macrophages following intracerebral LPS/IFNg injection. Panels A and B 
represent two different focal planes of the same histological section of the adult murine striatum 24 h following intracerebral injection of 
LPS/IFNg. Microglia, macrophages, and blood vessels are visualized in brown with tomato lectin, nuclei are visualized in blue with hematoxylin, 
and BG21 mRNA expression was visualized by photographic emulsion grains (black) with 33P label riboprobes. The arrow indicates a Golli-
MBP–expressing, lectin+ cell. 
Golli-MBP+ Macrophages are Detected Primarily in Perivascular Sites within the 
CNS During Acute EAE 
Expression of Golli-MBP by peripheral myeloid cells or even CNS-resident microglia has been 
hypothesized to contribute to susceptibility or exacerbation of CNS autoimmune responses directed 
against CNS myelin. Here, we examined whether the expression of Golli-MBP mRNA by CNS 
macrophages correlated either with clinical stage or histopathology in MBP-induced EAE. By in situ 
hybridization analysis, Golli-MBP expression could not be detected in any population of CNS 
macrophages in the CNS of either untreated mice or MBP-immunized mice while at preclinical stages of 
EAE (data not shown) consistent with our previous set of experiments. In stark contrast, Golli-MBP 
mRNA was readily detected in many CNS macrophages scattered throughout the entire cerebellum and 
spinal cord in mice exhibiting symptoms of acute EAE (characterized by complete paralysis of both hind 
limbs) (Fig. 3A, B).  
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FIGURE 3. Golli-MBP expression is differentially expressed in CNS macrophages during the acute 
and remission phases of EAE. Panels A and B represent histological sections from the cerebellum of a 
mouse with acute EAE (complete hind limb paralysis). Panels C and D represent histological sections 
from the cerebellum of a mouse that was in remission from acute EAE. Microglia, macrophages, and 
blood vessels are visualized in brown with tomato lectin, nuclei are visualized in blue with 
hematoxylin, and BG21 mRNA expression was visualized by photographic emulsion grains (black) 
with 33P label riboprobes. Arrows indicate a Golli-MBP–expressing, lectin+ cells. 
In general, the degree of neuroinflammation, microglial activation, and macrophage infiltration is 
much more robust in EAE than in the rapidly resolving LPS/IFNg model. Thus, it is interesting to note 
that while stellate, lectin+ cells did express Golli-MBP in the LPS/IFNg model, Golli-MBP+, lectin+ cells 
had much shorter, thicker process consistent with a highly activated phenotype during the acute stage of 
EAE. These Golli-MBP+, lectin+ cells were also localized primarily in perivascular sites in this EAE 
model. In MBP-immunized mice, which had recovered from clinical symptoms, Golli-MBP mRNA 
expression did not fully return to the untreated or preclinical phenotype even by the time that clinical 
symptoms had subsided (Fig 3C, D). Rather, Golli-MBP mRNA expression was now associated with 
occasional stellate-shaped parenchymal macrophages (with morphologies similar to that observed in the 
LPS/IFNg model) located within the cerebellum and spinal cord.  
What has this Comparative Analysis of Golli-MBP mRNA Expression Revealed 
about CNS Macrophage Biology? 
A few key conclusions can be drawn from these studies. First, cultured microglia and macrophages are 
important models that can be precisely manipulated, but these cultured models are not always completely 
predictive of microglial biology within the intact CNS. In vivo, the phenotype of CNS-resident microglia 
and acutely infiltrating macrophages is defined in part by their interactions with CNS neurons. Although 
the molecular nature of these interactions is only incompletely defined, several neuronally produced 
molecules, such as CD200, CD22, CCL21 and fractalkine, have demonstrated potential to modify 
myeloid responses to pathogenic signals[4,24]. In vitro, microglia and macrophages lack these phenotype-
determining interactions. The difference between in vitro and in vivo studies also suggests that CNS 
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insults that alter neuronal function will lead to significant alterations in the phenotype of all CNS 
macrophage populations[24]. 
Our data to date are consistent with Golli-MBP expression being enriched in a subset of 
hematogenously derived macrophages as compared to CNS-resident CD45lo microglia. However, 
irradiation chimeric studies will be necessary to identify conclusively the identity of the Golli-MBP+ 
CNS macrophage population. Our data do conclusively illustrate that even within a single pathology, 
there is significant heterogeneity in CNS macrophage phenotypes and thus likely functions. Future studies 
will be aimed at determining whether in vivo Golli-MBP+ CNS macrophages promote the proliferation 
and survival of oligodendrocyte and neuronal precursors. 
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